Home » Stocks » NYMX

Nymox Pharmaceutical Corporation (NYMX)

Stock Price: $2.40 USD -0.02 (-0.83%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 184.53M
Revenue (ttm) 116,000
Net Income (ttm) -13.16M
Shares Out 68.85M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $2.40
Previous Close $2.42
Change ($) -0.02
Change (%) -0.83%
Day's Open 2.42
Day's Range 2.32 - 2.45
Day's Volume 150,067
52-Week Range 1.69 - 4.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 months ago

HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide...

GlobeNewsWire - 5 months ago

HASBROUCK HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and ac...

GlobeNewsWire - 5 months ago

HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company's most important ongoing develo...

GlobeNewsWire - 7 months ago

HASBROUCK HEIGHTS, N.J., June 19, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations ...

GlobeNewsWire - 9 months ago

HASBROUCK HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and internation...

GlobeNewsWire - 10 months ago

HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a new peer review report was published today in the Wor...

GlobeNewsWire - 11 months ago

HASBROUCK HEIGHTS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the p...

GlobeNewsWire - 11 months ago

HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current January 2020 update on several important corporate ...

GlobeNewsWire - 1 year ago

HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on experi...

GlobeNewsWire - 1 year ago

HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report very positive fundamental news, that the Company has received ...

InvestorPlace - 1 year ago

Insiders only buy their stocks for one reason -- to make money. Here are 6 stocks to buy based on the recent insider buying.

Other stocks mentioned: CCL, GEF, HOFT, KR, PLAY
Seeking Alpha - 1 year ago

NYMX has been targeted by shorts like Richard Pearson, and longs have supported a completely opposite value statement.

About NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of... [Read more...]

Industry
Biotechnology
IPO Date
Dec 1, 1997
CEO
Dr. Paul Averback
Stock Exchange
NASDAQ
Ticker Symbol
NYMX
Full Company Profile

Financial Performance

In 2019, NYMX's revenue was $116,000, a decrease of -61.20% compared to the previous year's $299,000. Losses were -$13.16 million, 24.2% more than in 2018.

Financial Statements